Bone Biologics (BBLG) to Release Quarterly Earnings on Wednesday

Posted by Defense World Staff on Feb 18th, 2026

Bone Biologics (NASDAQ:BBLG – Get Free Report) is expected to announce its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.

Bone Biologics Price Performance

Shares of BBLG stock opened at $1.12 on Wednesday. The company’s fifty day moving average price is $1.64 and its two-hundred day moving average price is $1.96. The firm has a market capitalization of $2.02 million, a P/E ratio of -0.31 and a beta of 0.75. Bone Biologics has a 12 month low of $1.11 and a 12 month high of $7.50.

Hedge Funds Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC raised its position in shares of Bone Biologics Corp. (NASDAQ:BBLG – Free Report) by 113.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the quarter. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. 34.30% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Bone Biologics in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

View Our Latest Research Report on BBLG

About Bone Biologics

(Get Free Report)

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.